Evidence map›Paper›PMID 38467854›Full record

ArticleAbdominal radiology (New York)2024

Characterization of renal masses with MRI-based radiomics: assessment of inter-package and inter-observer reproducibility in a prospective pilot study.

Haitham Al-Mubarak, Octavia Bane, Nicolas Gillingham, Christopher Kyriakakos, Ghadi Abboud, Jordan Cuevas, Janette Gonzalez, Kirolos Meilika, Amir Horowitz, Hsin-Hui Vivien Huang and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Abdominal radiology (New York), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Haitham Al-MubarakBioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Octavia BaneBioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Nicolas GillinghamDepartment of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, Mount Sinai West, New York, NY, 10019, USA.
Christopher KyriakakosDepartment of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, New York, NY, USA.
Ghadi AbboudBioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Jordan CuevasBioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Janette GonzalezBioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Kirolos MeilikaDepartment of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Amir HorowitzPrecision Immunology Institute/Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Hsin-Hui Vivien HuangDepartment of Population Sciences and Health Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Jorge DazaDepartment of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Valentin FauveauBioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ketan BadaniDepartment of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Satish E ViswanathDepartment of Biomedical Engineering, School of Medicine, Case School of Engineering, Case Western Reserve University, Cleveland, OH, USA.
Bachir TaouliBioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Sara LewisBioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. sara.lewis@mountsinai.org.ORCID 0000-0002-4713-6453

Funding

RadxTools for assessing tumor treatment response on imagingU01CA248226 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI TIWARI, PALLAVI, VISWANATH, SATISH EASWAR · 2020 to 2022
$1.4M
NCI NIH HHS 1U01CA248226-01NCI NIH HHS U01 CA248226Peer Reviewed Cancer Research Program W81XWH-21-1-0345
6 · The paper itself

Abstract

objectivesTo evaluate radiomics features' reproducibility using inter-package/inter-observer measurement analysis in renal masses (RMs) based on MRI and to employ machine learning (ML) models for RM characterization.

methods32 Patients (23M/9F; age 61.8 ± 10.6 years) with RMs (25 renal cell carcinomas (RCC)/7 benign masses; mean size, 3.43 ± 1.73 cm) undergoing resection were prospectively recruited. All patients underwent 1.5 T MRI with T2-weighted (T2-WI), diffusion-weighted (DWI)/apparent diffusion coefficient (ADC), and pre-/post-contrast-enhanced T1-weighted imaging (T1-WI). RMs were manually segmented using volume of interest (VOI) on T2-WI, DWI/ADC, and T1-WI pre-/post-contrast imaging (1-min, 3-min post-injection) by two independent observers using two radiomics software packages for inter-package and inter-observer assessments of shape/histogram/texture features common to both packages (104 features; n = 26 patients). Intra-class correlation coefficients (ICCs) were calculated to assess inter-observer and inter-package reproducibility of radiomics measurements [good (ICC ≥ 0.8)/moderate (ICC = 0.5-0.8)/poor (ICC < 0.5)]. ML models were employed using reproducible features (between observers and packages, ICC > 0.8) to distinguish RCC from benign RM.

resultsInter-package comparisons demonstrated that radiomics features from T1-WI-post-contrast had the highest proportion of good/moderate ICCs (54.8-58.6% for T1-WI-1 min), while most features extracted from T2-WI, T1-WI-pre-contrast, and ADC exhibited poor ICCs. Inter-observer comparisons found that radiomics measurements from T1-WI pre/post-contrast and T2-WI had the greatest proportion of features with good/moderate ICCs (95.3-99.1% T1-WI-post-contrast 1-min), while ADC measurements yielded mostly poor ICCs. ML models generated an AUC of 0.71 [95% confidence interval = 0.67-0.75] for diagnosis of RCC vs. benign RM.

conclusionRadiomics features extracted from T1-WI-post-contrast demonstrated greater inter-package and inter-observer reproducibility compared to ADC, with fair accuracy for distinguishing RCC from benign RM. CLINICAL RELEVANCE: Knowledge of reproducibility of MRI radiomics features obtained on renal masses will aid in future study design and may enhance the diagnostic utility of radiomics models for renal mass characterization.

Indexed as

Contrast MediaKidney NeoplasmsMagnetic Resonance ImagingAgedCarcinoma, Renal CellFemaleHumansImage Interpretation, Computer-AssistedMachine LearningMaleMiddle AgedObserver VariationPilot ProjectsProspective StudiesRadiomicsReproducibility of ResultsContrast MediaClear cell renal cell carcinomaMagnetic resonance imagingRadiomicsRenal cell carcinomaRenal massReproducibility

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.